Your browser doesn't support javascript.
The impact of the COVID-19 pandemic on the Ontario Cervical Screening Program, colposcopy and treatment services in Ontario, Canada: a population-based study.
Meggetto, O; Jembere, N; Gao, J; Walker, M J; Rey, M; Rabeneck, L; Murphy, K J; Kupets, R.
  • Meggetto O; Ontario Health (Cancer Care Ontario), Toronto, ON, Canada.
  • Jembere N; Ontario Health (Cancer Care Ontario), Toronto, ON, Canada.
  • Gao J; Ontario Health (Cancer Care Ontario), Toronto, ON, Canada.
  • Walker MJ; Ontario Health (Cancer Care Ontario), Toronto, ON, Canada.
  • Rey M; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Rabeneck L; Ontario Health (Cancer Care Ontario), Toronto, ON, Canada.
  • Murphy KJ; Ontario Health (Cancer Care Ontario), Toronto, ON, Canada.
  • Kupets R; Department of Medicine, University of Toronto, Toronto, ON, Canada.
BJOG ; 128(9): 1503-1510, 2021 08.
Article in English | MEDLINE | ID: covidwho-1315738
ABSTRACT

OBJECTIVE:

To describe the immediate impact of the COVID-19 pandemic on cervical screening, colposcopy and treatment volumes in Ontario, Canada.

DESIGN:

Population-based retrospective observational study.

SETTING:

Ontario, Canada. POPULATION People with a cervix age of 21-69 years who completed at least one cervical screening cytology test, colposcopy or treatment procedure for cervical dysplasia between January 2019 and August 2020.

METHODS:

Administrative databases were used to compare cervical screening cytology, colposcopy and treatment procedure volumes before (historical comparator) and during the first 6 months of the COVID-19 pandemic (March-August 2020). MAIN OUTCOME

MEASURES:

Changes in cervical screening cytology, colposcopy and treatment volumes; individuals with high-grade cytology awaiting colposcopy.

RESULTS:

During the first 6 months of the COVID-19 pandemic, the monthly average number of cervical screening cytology tests, colposcopies and treatments decreased by 63.8% (range -92.3 to -41.0%), 39.7% (range -75.1 to -14.3%) and 31.1% (range -43.5 to -23.6%), respectively, when compared with the corresponding months in 2019. Between March and August 2020, on average 292 (-51.0%) fewer high-grade cytological abnormalities were detected through screening each month. As of August 2020, 1159 (29.2%) individuals with high-grade screening cytology were awaiting follow-up colposcopy.

CONCLUSIONS:

The COVID-19 pandemic has had a substantial impact on key cervical screening and follow-up services in Ontario. As the pandemic continues, ongoing monitoring of service utilisation to inform system response and recovery is required. Future efforts to understand the impact of COVID-19-related disruptions on cervical cancer outcomes will be needed. TWEETABLE ABSTRACT COVID-19 has had a substantial impact on cervical screening and follow-up services in Ontario, Canada.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaginal Smears / Uterine Cervical Neoplasms / Colposcopy / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Middle aged / Young adult Country/Region as subject: North America Language: English Journal: BJOG Journal subject: Gynecology / Obstetrics Year: 2021 Document Type: Article Affiliation country: 1471-0528.16741

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaginal Smears / Uterine Cervical Neoplasms / Colposcopy / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Middle aged / Young adult Country/Region as subject: North America Language: English Journal: BJOG Journal subject: Gynecology / Obstetrics Year: 2021 Document Type: Article Affiliation country: 1471-0528.16741